BCAL Diagnostics Limited

As of June 30, 2025, BCAL Diagnostics Limited carries a market capitalization of 23.06M, placing it among publicly traded companies globally. Its enterprise value stands at 20.91M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

BCAL Diagnostics Limited's next confirmed earnings release is scheduled for February 23, 2027.

As of June 30, 2025, BCAL Diagnostics Limited has 365.97M shares outstanding.

These figures are as of June 30, 2025. The price-to-sales ratio is 1,047.03, and the price-to-book ratio stands at 3.71.

These figures are as of June 30, 2025. The EV/Sales ratio of 966.50 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 20.91M versus a market cap of 23.06M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2025, BCAL Diagnostics Limited maintains a current ratio of 2.32, meaning it holds 2.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 38.24, indicating elevated leverage, while an interest coverage ratio of -195.98 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2025, BCAL Diagnostics Limited posted a negative return on equity (ROE) of -97.79, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -65.31, reflecting losses generated across the asset base.

As of the close on October 22, 2026, BCAL Diagnostics Limited's stock has declined approximately 16.67% over the past 52 weeks. The 50-day moving average sits at 0.07, while the 200-day moving average is 0.09.

Over the twelve months ended June 30, 2025, BCAL Diagnostics Limited generated 21,637.00 in revenue and converted that into -7.24M in net income, yielding earnings per share of -0.02. EBITDA reached -8.96M, while operating income came in at -9.96M.

As of June 30, 2025, BCAL Diagnostics Limited holds 4.52M in cash and equivalents against 2.38M in total debt, resulting in a net debt position of -2.83M. Total book value stands at 6.22M, with working capital of 4.09M providing operational flexibility.

These figures cover the twelve months ended June 30, 2025.

These figures cover the twelve months ended June 30, 2025. The operating margin of -46,043.03 and net profit margin of -33,465.98 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2025. Total shareholder yield is negative at -21.57, meaning BCAL Diagnostics Limited raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2025, BCAL Diagnostics Limited has an Altman Z-Score of -3.04, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.